| 22.04.2025 16:59 | W7L, TPK, TST | UK earnings, trading statements calendar - next 7 days | Alliance |
| 22.04.2025 08:32 | AZN, HCM | Hutchmed China completes enrolment for gastric cancer drug trial | Alliance |
| 22.04.2025 07:00 | AZN | Enhertu combination improved PFS in 1L HER2+ mBC | RNS |
| 11.04.2025 17:30 | AZN | Result of AGM | RNS |
| 09.04.2025 10:08 | CAML, TSTL, BHP | LONDON BROKER RATINGS: Kepler raises Rolls-Royce; UBS cuts ITV | Alliance |
| 09.04.2025 05:58 | AZN | Daiichi Sankyo and AstraZeneca secure EU approval for Datroway | Alliance |
| 04.04.2025 14:16 | JADE, AZN | UK shareholder meetings calendar - next 7 days | Alliance |
| 04.04.2025 09:44 | AZN | AstraZeneca gets EU approval for cancer treatments Enhertu and Imfinzi | Alliance |
| 04.04.2025 07:05 | AZN | Imfinzi approved in EU for AEGEAN | RNS |
| 04.04.2025 07:00 | AZN | Enhertu approved in EU in post-ET breast cancer | RNS |
| 01.04.2025 15:00 | AZN | Total Voting Rights | RNS |
| 31.03.2025 09:43 | AZN | AstraZeneca reports positive developments with assets in US and EU | Alliance |
| 31.03.2025 07:05 | AZN | Calquence recommended for EU approval in 1L MCL | RNS |
| 31.03.2025 07:00 | AZN | Imfinzi approved in the US for bladder cancer | RNS |
| 28.03.2025 09:22 | SUPR, VTY, BRBY | LONDON BROKER RATINGS: Next gets price target bumps after results | Alliance |
| 25.03.2025 09:04 | AZN | AstraZeneca highlights new Tagrisso data in lung cancer trials
| Alliance |
| 21.03.2025 14:25 | AGL, AZN | Angle hails successful completion of Eisai contract; approval by Astra | Alliance |
| 21.03.2025 11:27 | AZN | AstraZeneca to invest USD2.5 billion in new Beijing strategic centre | Alliance |
| 21.03.2025 10:58 | AZN | AZN invests $2.5bn in Beijing R&D & manufacturing | RNS |
| 20.03.2025 14:31 | AZN, HCM | IN BRIEF: Hutchmed highlights positive lung cancer test results | Alliance |
| 17.03.2025 14:22 | SHEL, AZN, PUAL | UK dividends calendar - next 7 days | Alliance |
| 17.03.2025 08:57 | AZN | AstraZeneca to pay up to USD1 billion for cell therapy firm, EsoBiotec | Alliance |
| 17.03.2025 07:10 | AZN | Eneboparatide Phase III trial met primary endpoint | RNS |
| 17.03.2025 07:05 | AZN | Imfinzi approved in EU for limited-stage SCLC | RNS |
| 17.03.2025 07:00 | AZN | AstraZeneca to acquire EsoBiotec | RNS |
| 12.03.2025 18:00 | AZN | Holding(s) in Company | RNS |
| 07.03.2025 15:00 | AZN | Director/PDMR Shareholding | RNS |
| 07.03.2025 11:00 | AZN | Notice of AGM | RNS |
| 07.03.2025 09:59 | AZN | AstraZeneca finds Imfinzi improves survival rates for gastric cancers | Alliance |
| 07.03.2025 07:00 | AZN | Imfinzi improved EFS in early-stage gastric cancer | RNS |
| 06.03.2025 15:00 | AZN | Director/PDMR Shareholding | RNS |
| 05.03.2025 15:00 | AZN | Director/PDMR Shareholding | RNS |
| 03.03.2025 15:00 | AZN | Total Voting Rights | RNS |
| 03.03.2025 11:13 | AZN | AstraZeneca lung cancer therapy Imfinzi recommended for EU approval | Alliance |
| 03.03.2025 07:00 | AZN | Imfinzi recommended for EU approval for AEGEAN | RNS |
| 28.02.2025 15:26 | AZN | AstraZeneca breast cancer therapy wins recommendation for EU approval | Alliance |
| 28.02.2025 13:00 | AZN | Enhertu recommended in EU in post-ET breast cancer | RNS |
| 26.02.2025 09:27 | AZN | AstraZeneca's camizestrant has benefit in advanced breast cancer trial | Alliance |
| 26.02.2025 07:00 | AZN | Camizestrant improved PFS in 1L HR+ breast cancer | RNS |
| 19.02.2025 07:00 | AZN | Filing of Form 20-F with SEC | RNS |
| 18.02.2025 11:00 | AZN | Annual Financial Report | RNS |
| 18.02.2025 07:00 | AZN | Directorate Change | RNS |
| 13.02.2025 14:02 | RESI, PRSR, WINK | UK dividends calendar - next 7 days | Alliance |
| 13.02.2025 09:35 | CTEC, AZN, SMIN | LONDON BROKER RATINGS: UBS raises AstraZeneca to 'buy' | Alliance |
| 12.02.2025 09:58 | IAG, ADM, EZJ | LONDON BROKER RATINGS: Morgan Stanley likes Astra; HSBC cuts Spectris | Alliance |
| 11.02.2025 09:52 | STAN, NWG, LLOY | LONDON BROKER RATINGS: Peel Hunt raises Fevertree to 'hold' | Alliance |
| 10.02.2025 09:59 | IAG, AZN, AGL | LONDON BROKER RATINGS: Deutsche Bank raises Victrex, cuts Fevertree | Alliance |
| 06.02.2025 08:42 | AZN | Cancer drugs help drive fourth-quarter sales beat at AstraZeneca | Alliance |
| 06.02.2025 07:00 | AZN | Final Results | RNS |
| 04.02.2025 10:41 | AZN, GSK, INDV | IN BRIEF: Indivior completes USD100 million share buyback | Alliance |
| 03.02.2025 17:00 | AZN | Total Voting Rights | RNS |
| 03.02.2025 08:34 | AZN | AstraZeneca's Imfinzi endorsed for EU approval for lung cancer care | Alliance |
| 03.02.2025 07:00 | AZN | Imfinzi recommended for EU approval for LS-SCLC | RNS |
| 31.01.2025 18:20 | AZN | AstraZeneca pulls UK investment after dispute over Government support | Alliance |
| 30.01.2025 11:26 | JTC, CPG, WOSG | UK earnings, trading statements calendar - next 7 days | Alliance |
| 28.01.2025 13:43 | AZN, API, FCSS | EXECUTIVE CHANGES: Smithson changes chairs; British Land taps new COO | Alliance |
| 28.01.2025 07:00 | AZN | Enhertu approved in US for breast cancer post ET | RNS |
| 28.01.2025 07:00 | AZN | AstraZeneca's and Daiichi Sankyo's Enhertu wins new approval in US | Alliance |
| 23.01.2025 20:34 | AZN | AstraZeneca makes USD570 million investment in Canada in pipeline push | Alliance |
| 20.01.2025 09:56 | ABDP, SFR, SYNT | LONDON BROKER RATINGS: Jefferies raises Spirax; Peel Hunt cuts Grainger | Alliance |
| 20.01.2025 08:38 | AZN | AstraZeneca and Daiichi's Datroway wins US FDA breast cancer approval | Alliance |
| 20.01.2025 07:00 | AZN | Dato-DXd approved in US for HR+ breast cancer | RNS |
| 17.01.2025 08:16 | AZN | AstraZeneca's Calquence gets US approval for mantle cell lymphoma | Alliance |
| 17.01.2025 07:00 | AZN | Calquence combination approved in US for 1L MCL | RNS |
| 14.01.2025 12:07 | AZN, HCM | IN BRIEF: Hutchmed lung cancer treatment Orpathys approved in China | Alliance |
| 13.01.2025 09:37 | DAL, THS, WISE | LONDON BROKER RATINGS: Deutsche Bank cuts Direct Line to 'hold' | Alliance |
| 13.01.2025 09:19 | AZN | AstraZeneca and Daiichi Sankyo cheer priority US review of cancer drug | Alliance |
| 09.01.2025 11:25 | AZN | AstraZeneca breast cancer drug Lynparza given green light for NHS use | Alliance |
| 02.01.2025 15:00 | AZN | Total Voting Rights | RNS |
| 02.01.2025 10:46 | AZN, HCM | Hutchmed China disposes of 45% stake in Shanghai joint venture | Alliance |
| 27.12.2024 09:11 | AZN, SYNC | Syncona investee sells assets to AstraZeneca for USD12 million | Alliance |
| 24.12.2024 08:20 | AZN | AstraZeneca and Daiichi withdraw EU application for lung cancer drug | Alliance |
| 24.12.2024 07:00 | AZN | Dato-DXd NSQ NSCLC application withdrawn in EU | RNS |
| 23.12.2024 10:13 | AZN | AstraZeneca receives EU approval for Tagrisso lung cancer treatment | Alliance |
| 23.12.2024 07:00 | AZN | Tagrisso approved in EU based on LAURA trial | RNS |
